As of 2024-12-11, the Intrinsic Value of Hansa Biopharma AB (HNSA.ST) is (1,440.11) SEK. This HNSA.ST valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 30.52 SEK, the upside of Hansa Biopharma AB is -4,818.60%.

The range of the Intrinsic Value is (17,113.24) - (765.84) SEK

Note: result may not be accurate due to the invalid valuation result of DCF model.

	Range	Selected	Upside
a
DCF (Growth 5y)	(17,113.24) - (765.84)	(1,440.11)	-4818.6%
DCF (Growth 10y)	(1,805.69) - (43,222.12)	(3,513.42)	-11611.9%
DCF (EBITDA 5y)	(639.79) - (844.23)	(1,234.50)	-123450.0%
DCF (EBITDA 10y)	(1,538.75) - (2,338.88)	(1,234.50)	-123450.0%
Fair Value	-48.28 - -48.28	-48.28	-258.18%
P/E	(195.04) - (196.01)	(188.76)	-718.5%
EV/EBITDA	(153.78) - (166.16)	(158.40)	-619.0%
EPV	(109.07) - (189.51)	(149.29)	-589.2%
DDM - Stable	(103.06) - (1,360.05)	(731.55)	-2497.0%
DDM - Multi	(551.97) - (5,908.69)	(1,026.85)	-3464.5%